At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 576 enrolled
Drug / intervention
SB-742457 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating SB-742457, Donepezil, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 576 participants across 72 sites in 11 countries.
Detailed Summary
The study is designed to investigate the efficacy, safety and tolerability of SB-742457 versus placebo in subjects with mild-to-moderate Alzheimer's disease. SB-742457 is an experimental treatment which increases the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesBulgaria, Chile, Czechia, Estonia, Germany, Greece, Mexico, Poland, Russia, South Africa, South Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartJul 2008
Primary CompletionMar 2010
Study CompletionMar 2010
TodayJul 2026
First PostedJul 2, 2008
Enrollment StartJul 4, 2008
Primary CompletionMar 1, 2010
Study CompletionMar 9, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18 years ago
Interventions
SB-742457drug
investigational drug
Donepezildrug
comparator
Placebodrug
comparator